1. Search Result
Search Result
Results for "

SUMO

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

3

Natural
Products

278

Recombinant Proteins

11

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114304
    COH000
    1 Publications Verification

    E1/E2/E3 Enzyme Cancer
    COH000 is an allosteric, covalent and irreversible inhibitor of ubiquitin-like 1-activating enzyme (SUMO-activating enzyme) (E1), with an IC50 of 0.2 μM for SUMOylation in vitro .
    COH000
  • HY-N2360
    Hinokiflavone
    2 Publications Verification

    E1/E2/E3 Enzyme Apoptosis MMP ClpP Infection Inflammation/Immunology Cancer
    Hinokiflavone is a novel modulator of pre-mRNA splicing activity extracted from plants with anti-inflammatory, anti-tumor and antiviral activities. Hinokiflavone is also a potent inhibitor for matrix metalloproteinases (MMPs). Hinokiflavone attenuates the virulence of Methicillin (HY-121544)-resistant staphylococcus aureus by inhibiting caseinolytic protease P (ClpP) with an IC50 value of 34.36 mg/mL. Hinokiflavone induces apoptosis via the reactive oxygen species-mitochondria-mediated apoptotic pathway and inhibits tumor cell migration and invasion. Hinokiflavone is a SUMO protease inhibitor against sentrin-specific protease 1 (SENP1) activity .
    Hinokiflavone
  • HY-139662

    E1/E2/E3 Enzyme Cancer
    HB007 is a small ubiquitin-related modifier 1 (SUMO1) degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers .
    HB007
  • HY-111789
    Subasumstat
    10+ Cited Publications

    TAK-981

    E1/E2/E3 Enzyme Inflammation/Immunology Cancer
    Subasumstat (TAK-981) is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities .
    Subasumstat
  • HY-108702
    ML-792
    Maximum Cited Publications
    24 Publications Verification

    E1/E2/E3 Enzyme Cancer
    ML-792 is a potent and selective inhibitor of SAE/SUMO1 and SAE/SUMO2 in enzymatic assays (IC50 values of 3 and 11 nM, respectively) compared with NAE/NEDD8 and UAE/ubiquitin (IC50> values of 32 μM and >100 μM, respectively) .
    ML-792
  • HY-E70372

    Biochemical Assay Reagents Others
    SUMO Protease is highly specific for proteins containing small ubiquitin-like modifier (SUMO) tags. SUMO Protease can be used to regulates the proteins splicing, controlls protein structure and function in vitro .
    SUMO Protease
  • HY-RS14025

    Small Interfering RNA (siRNA) Others

    SUMO1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUMO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUMO1 Human Pre-designed siRNA Set A
    SUMO1 Human Pre-designed siRNA Set A
  • HY-RS14026

    Small Interfering RNA (siRNA) Others

    SUMO2 Human Pre-designed siRNA Set A contains three designed siRNAs for SUMO2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUMO2 Human Pre-designed siRNA Set A
    SUMO2 Human Pre-designed siRNA Set A
  • HY-RS14027

    Small Interfering RNA (siRNA) Others

    SUMO3 Human Pre-designed siRNA Set A contains three designed siRNAs for SUMO3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUMO3 Human Pre-designed siRNA Set A
    SUMO3 Human Pre-designed siRNA Set A
  • HY-RS14028

    Small Interfering RNA (siRNA) Others

    SUMO4 Human Pre-designed siRNA Set A contains three designed siRNAs for SUMO4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUMO4 Human Pre-designed siRNA Set A
    SUMO4 Human Pre-designed siRNA Set A
  • HY-158706

    E1/E2/E3 Enzyme Cancer
    SAE-IN-2 (compound 6) is a potent inhibitor of sumo activating enzume (SAE), with the IC50 of 27.8 nM .
    SAE-IN-2
  • HY-Y0493

    HOOBt

    STAT HIV Infection Cancer
    HODHBt (HOOBt) inhibits STAT5-SUMO interaction by blocking SUMOylation of phosphorylated STAT5. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer .
    HODHBt
  • HY-110273

    Calcium Channel E1/E2/E3 Enzyme Cardiovascular Disease
    N106 is a first-in-class sarcoplasmic reticulum calcium ATPase (SERCA2a) SUMOylation activator. N106 directly activates the SUMO-activating enzyme, E1 ligase. N106 can be used for heart failure research .
    N106
  • HY-103435
    Vialinin A
    2 Publications Verification

    Terrestrin A

    Deubiquitinase Inflammation/Immunology Cancer
    Vialinin A (Terrestrin A) is a p-terphenyl compound with antioxidant properties . Vialinin A is a potent inhibitor of TNF-α, USP4, USP5, and sentrin/SUMO-specific protease 1 (SENP1). Vialinin A (Terrestrin A) can be used for autoimmune diseases and cancer research .
    Vialinin A
  • HY-151358

    Others Cancer
    SENP2-IN-1 (compound 77) is a selective SENP2 inhibitor. SENP2-IN-1 shows inhibitory activities with IC50s of 1.3, 0.69 and 22.7 μM for SENP1, SENP2 and SENP5, respectively. SENP2-IN-1 can be used for the research of cancer .
    SENP2-IN-1
  • HY-134594

    E1/E2/E3 Enzyme Cancer
    SENP1-IN-1 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 29. SENP1-IN-1 is developed for tumor radiosensitivity enhancement .
    SENP1-IN-1
  • HY-134595

    E1/E2/E3 Enzyme Cancer
    SENP1-IN-2 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 30. SENP1-IN-2 is developed for tumor radiosensitivity enhancement .
    SENP1-IN-2
  • HY-134596

    E1/E2/E3 Enzyme Cancer
    SENP1-IN-3 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 17. SENP1-IN-3 is developed for tumor radiosensitivity enhancement .
    SENP1-IN-3
  • HY-134597

    E1/E2/E3 Enzyme Cancer
    SENP1-IN-4 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 21. SENP1-IN-4 is developed for tumor radiosensitivity enhancement .
    SENP1-IN-4
  • HY-N0330
    Momordin Ic
    3 Publications Verification

    Apoptosis Autophagy PI3K c-Myc Metabolic Disease Inflammation/Immunology Cancer
    Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .
    Momordin Ic
  • HY-N0330R

    Apoptosis Autophagy PI3K c-Myc Metabolic Disease Inflammation/Immunology Cancer
    Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .
    Momordin Ic (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: